Literature DB >> 19358617

Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.

Cheryl D Bushnell1, Cathleen S Colón-Emeric.   

Abstract

Older adults are not only at higher risk of experiencing stroke, but also have multiple co-morbidities that make treatment for secondary stroke prevention challenging. Very few clinical trials specifically related to secondary stroke prevention treatment efficacy have focused on the oldest-old (>or=85 years) and, therefore, evidence-based recommendations for treatment specific to this population are not available. Some of the special considerations for stroke prevention treatments in older patients include careful titration of blood-pressure-lowering drugs to avoid hypotension, the risk of haemorrhagic stroke with HMG-CoA reductase inhibitors (statins) and weighing the risk of recurrent ischaemia versus bleeding in patients taking antiplatelet or anticoagulant therapy. The risk of peri-procedural complications appears to be high with both carotid angioplasty and stenting and carotid endarterectomy in older patients with carotid stenosis. Other common issues in older patients include adverse drug events, recognizing the risk of dementia, depression and osteoporosis and deciding when to discontinue secondary stroke prevention. In this review, we provide the practitioner with the evidence related to specific approaches to secondary stroke prevention in older patients, and identify the knowledge gaps that currently limit our ability to appropriately treat this vulnerable population.

Entities:  

Mesh:

Year:  2009        PMID: 19358617      PMCID: PMC3740382          DOI: 10.2165/00002512-200926030-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  146 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  Statin-associated myopathy.

Authors:  Paul D Thompson; Priscilla Clarkson; Richard H Karas
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

3.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Authors:  Deepak L Bhatt; Keith A A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Danielle M Brennan; Liz Fabry-Ribaudo; Joan Booth; Eric J Topol
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

4.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

5.  Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.

Authors:  L B Goldstein; P Amarenco; M Szarek; A Callahan; M Hennerici; H Sillesen; J A Zivin; K M A Welch
Journal:  Neurology       Date:  2007-12-12       Impact factor: 9.910

6.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

7.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

Authors:  Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

8.  Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.

Authors: 
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

9.  Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group.

Authors:  R W Hobson; D G Weiss; W S Fields; J Goldstone; W S Moore; J B Towne; C B Wright
Journal:  N Engl J Med       Date:  1993-01-28       Impact factor: 91.245

10.  Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults.

Authors:  Joseph V Agostini; Mary E Tinetti; Ling Han; Gail McAvay; Joanne M Foody; John Concato
Journal:  J Am Geriatr Soc       Date:  2007-03       Impact factor: 5.562

View more
  3 in total

1.  Navigating the gray zones of stroke management for a graying population.

Authors:  Meng Lee; Bruce Ovbiagele
Journal:  Cerebrovasc Dis       Date:  2010-03-30       Impact factor: 2.762

2.  Change in Prescribing for Secondary Prevention of Stroke and Coronary Heart Disease in Finnish Nursing Homes and Assisted Living Facilities.

Authors:  Natali Jokanovic; Hannu Kautiainen; J Simon Bell; Edwin C K Tan; Kaisu H Pitkälä
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

3.  Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders.

Authors:  Eva Zupanic; Milica G Kramberger; Mia von Euler; Bo Norrving; Bengt Winblad; Juraj Secnik; Johan Fastbom; Maria Eriksdotter; Sara Garcia-Ptacek
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.